Diaceutics (LON:DXRX) Share Price Crosses Below 50 Day Moving Average – Should You Sell?

Diaceutics PLC (LON:DXRX)’s share price crossed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of GBX 187.36 and traded as low as GBX 178.50. Diaceutics shares last traded at GBX 184, with a volume of 151,555 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group reiterated a “buy” rating and issued a GBX 215 price target on shares of Diaceutics in a report on Tuesday. Two research analysts have rated the stock with a Buy rating. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of GBX 215.

Diaceutics Trading Down 0.5%

The company has a market capitalization of £164.85 million, a P/E ratio of -606.25 and a beta of 0.88. The company has a debt-to-equity ratio of 5.40, a current ratio of 2.55 and a quick ratio of 9.92. The firm has a fifty day moving average price of GBX 189.12 and a 200-day moving average price of GBX 160.98.

Diaceutics (LON:DXRX) last issued its quarterly earnings results on Tuesday, September 22nd. The company reported GBX (3.27) EPS for the quarter. Diaceutics had a negative net margin of 0.66% and a negative return on equity of 0.68%. On average, equities research analysts anticipate that Diaceutics PLC will post 1.01 earnings per share for the current year.

Insider Buying and Selling at Diaceutics

In other news, insider Ryan Gerard Keeling sold 500,000 shares of the firm’s stock in a transaction on Thursday, November 12th. The stock was sold at an average price of GBX 190, for a total transaction of £950,000. Also, insider Jordan Clark sold 250,000 shares of Diaceutics stock in a transaction on Thursday, November 12th. The stock was sold at an average price of GBX 190, for a total value of £475,000. Insiders sold 2,600,000 shares of company stock worth $494,000,000 in the last quarter. 26.23% of the stock is currently owned by company insiders.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.